At birth, doctors gave Julien Ferrer only a slim chance of surviving a rare childhood bone disease. Fifteen years on, the French teen is living a normal life in Canada, where he received cutting-edge treatment—and new hope for the future.

Julien was born in 2002 in Perpignan, in southern France. Right away, his parents Melanie and John Ferrer said they noticed some issues. "He was a baby, average in most ways. But he wasn't growing well, ate very little and cried a lot," his mother recalled in an interview with AFP.

The first series of X-rays showed his tiny infant bones were "translucent" and he lacked muscle mass, she said. His original doctors did not know what to make of it. But specialists later determined he was suffering from a genetic disorder called hypophosphatasia (HPP), which is characterized by abnormal bone development.

The disease is caused by an inability to absorb minerals like calcium or phosphorus—meaning a person's bones are fragile. At the time, there were only eight known cases in France. Doctors gave Julien little chance of survival.

His distraught parents scoured the Internet for information, which Melanie said "was the worst thing to do" because the medical websites they visited said most cases for infants under the age of 18 months ended in death.

In subsequent years, the Ferrers did all they could to meet Julien's special needs while trying to ensure he could play with children his age—even if he needed a wheelchair to get around.

They reached out to others with similar ailments and launched an association to fund hypophosphatasia research. They even helped organize the world's first international symposium on the disorder in 2008.

But then, a turning point: Canadian researchers attending the conference announced they are launching a clinical trial for a new treatment. And a few weeks later, they offer Julien a place in the trial in Winnipeg.

Cheryl Greenberg, a geneticist at the University of Manitoba who led a clinical trial of treatment that Julien received, points at X-rays of people afflicted with hypophosphatasia.

A new hope

Julien received his first treatment at the Winnipeg Children's Hospital in January 2010, when he was seven years old. "By Easter, he was walking," said his mother, her eyes wide with astonishment as she recalled the quick transformation.

For a while, the Ferrers traveled back and forth between Canada and France for Julien's quarterly treatments, due to the limited conditions of their visas. But in 2012, exhausted by the grueling transatlantic trips, they decided to immigrate to Canada, where Melanie says there are better options for people with disabilities than in France.

"We had to rebuild our lives from scratch—we were 33, it was kind of scary," she said. Melanie Ferrer helps her son Julien with one of the three injections he needs per week to treat his condition. The couple bought a house in the suburbs of Winnipeg, and both got jobs at the French-language Saint Boniface University in the city's historic French Quarter.

'Pretty normal life.'

Julien, now 15, is healthy and active. He attends a high school named after the province's founding father, Louis Riel, only two blocks from the university where his parents work. Like other teenagers, he dreams of the future, with hopes for a career either in the theater or video game design.

The experimental drug Julien takes was authorized for sale in Canada at the end of 2017 and has been covered by his French government health plan since January. For Julien's parents, the cure is simply "a miracle."